Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06680323 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Identification of Risk Factors, Exposomics and Genetic Susceptibility of Melanoma in Children, Adolescents and Young Adults

Study acronym: ExpoMel
StatusUnknown
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 8, 2024 (before its estimated May 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of this study is the identification of environmental and genetic factors involved in the risk and progression of melanoma in children, adolescents and young adults (CAYA). The secondary objectives are to generate a model integrating the genetic and environmental factors to estimate the risk of developing melanoma and improve the primary prevention of melanoma through evidence-based interpretation of environmental risk.
Trial Details
NCT Number NCT06680323
Lead Sponsor University Hospital Tuebingen
Collaborators: Hospital Clinic of Barcelona, University Of Perugia, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Karolinska University Hospital, Leibniz Research Institute for Environmental Medicine Düsseldorf, Princess Maxima Center for Pediatric Oncology, Medical University of Gdansk
Conditions
(from sponsor)		 Melanoma, Spitzoid Melanoma, Congenital Nevi
Related terms Genetic Predisposition to Disease, Melanoma
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov